Our Mission. Qlibrium is committed to helping patients live life to the fullest by developing and innovating discreet and flexible drug delivery solutions.
Our Aim. Qlibrium is developing a highly flexible platform for delivering injectable drugs into subcutaneous tissue with a wearable on-body delivery system that brings dramatic improvements over existing devices to both users and to pharmaceutical companies.
Who is Qlibrium
Qlibrium, formerly known as Cam Med, began with a simple question: Why can’t a pump for injectable drugs work like an extension of the body? For patients with chronic conditions such as diabetes, Parkinson’s disease, hormone deficiencies, and blood disorders, as well as other conditions that require frequent subcutaneous injections of drugs, a better wearable experience translates into improved compliance and outcomes.
Qlibrium has been working to bring our vision of marked simplicity to reality with development of the patent-protected QLib platform for pre-filled subcutaneous delivery of drugs and QForma for diabetes patients.
Our innovative work has been recognized with prizes from MassChallenge, the Centre for Advancement of Science in Space, the New England Pediatric Device Consortium, the Massachusetts Medical Device Development Center, and we are a member of JLABS, part of Johnson & Johnson Innovation.
Today, we are working with pharmaceutical partners to deliver a better experience to patients because patient acceptance is key to compliance.
Larry co-founded Cam Med, now known as Qlibrium, in 2014. He saw first-hand the challenges his mother faced throughout her life as she took multiple medications to manage her health, and he knew there must be a better way. Based in Asia for much of his career as a strategy consultant, he became deeply involved with the NGO Save the Children and recognized the need to reduce the cost of healthcare technologies dramatically while making them usable at home, whether in a modern city or a rural village. These experiences contributed to Qlibrium’s mission of helping ease the burden on people to manage their diseases by innovating patient-centric, flexible, and accessible drug delivery solutions. Larry has 25 years of global experience at the strategy consulting firms Bain & Company, Boston Consulting Group, and Oliver Wyman, building, leading and growing businesses and relevant technologies. He was founding Chairman and Board Director of Save the Children Hong Kong. He has an MBA and MA from the Wharton School and Lauder Institute, where he was a Palmer Scholar, and an AB from Harvard College.
Zhifei is co-founder and CTO of Qlibrium. He is the co-inventor of Qlibrium’s unique patent-protected technology, which is core to Qlibrium’s portfolio of products and is changing the industry. He has more than 10 years’ experience designing and developing miniaturized devices. His PhD research has led to multiple publications, patents, and the creation of another company called Kytopen Inc., which is pioneering a novel and non-viral process to engineer human cells for therapeutic applications in immuno-oncology and genetic disorders. He holds a BS from Shanghai Jiao Tong University and an MS and PhD from MIT. Dr. Ge has been awarded Medtech’s Rising Star 2017 by MD+DI, and 40 Under 40 by Medtech Boston in 2018.
John is a product development innovator with 30 years of diverse experience. Prior to joining Qlibrium, in his 10 years at Insulet Corporation, John was a leader on the vision and original development of the Omnipod on-body drug delivery system. John also was a Principal at Continuum Innovation for nearly a decade where he led innovation and product development programs across multiple industries. John holds several patents related to wearable drug delivery technologies and other innovative product categories. John earned his BS in Mechanical Engineering with honors from the University of Lowell, and also earned an MS in Engineering from the University of Massachusetts Lowell.
Richard is a medical device and life science sales/marketing executive with a career spanning more than 25 years. He has held leadership roles in sales and marketing at innovative medical companies including NeoMatrix, OvaScience and Insulet, having launched several disruptive technologies that have improved patients’ lives worldwide. Richard developed a passion for drug delivery systems while at Insulet, where he led drug delivery alliance management and partner development. He brings a unique perspective to the on-body wearable space as a user of a wearable insulin pump to manage his type 1 diabetes. His unique personal and professional perspective is helping Qlibrium create a drug delivery platform built on the foundation of a superior user experience. Richard also is an active volunteer member of the Joslin Diabetes Center Patient Family Advisory Council (PFAC). He has a BS in Business Administration (Marketing) from California State University, Sacramento.
Partnerships and Recognition
MassChallenge, Gold Prize
Headquartered in the United States with locations in Boston, Israel, Mexico, Rhode Island, Switzerland, and Texas, MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world — for zero-equity taken.
The nonprofit Center for the Advancement of Science in Space (CASIS) manages the U.S. portion of the ISS, which is available for use by non-NASA U.S. government agencies, academic institutions, and the private sector, providing these customers access to a permanent microgravity setting, a powerful vantage point in low Earth orbit, and the extreme and varied environments of space.
JDRF, Grant Recipient
JDRF is the leading global organization funding type 1 diabetes (T1D) research and has partnered with Qlibrium, formerly known as Cam Med, to develop a flexible wearable pump for automated insulin delivery systems.
T1D Exchange Diabetes Innovation Challenge, 3rd Place Winner
Third place winner at 2018 competition organized by the T1D Exchange, a nonprofit research organization dedicated to accelerating therapies and improving care for people living with type 1 diabetes.
Mass Life Sciences Center, UP Grant Recipient
The Massachusetts Life Sciences Center is an economic development and investment agency with a mission of supporting the growth and development of the life sciences in Massachusetts.
New England Pediatric Device Consortium, Grant Recipient
NEPDC is a multidisciplinary, multi-institutional, collaborative consortium that provides infrastructure, expert consultation, and execution of technology translation and commercialization to innovators of pediatric technologies.
MedTech Innovator, Top 100
MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Their mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system.
M2D2 New Venture Competition, Finalist
The Massachusetts Medical Device Development Center (M2D2) is a lifeline for the state’s smaller medical device companies, offering inventors and executives easy, affordable, and coordinated access to world-class researchers and resources at the UMass Lowell and the UMass Medical School campuses of the University of Massachusetts.
JLABS, Resident Company
To learn more about the QLib OBDS platform for pharmaceutical companies and schedule a demo, contact us
Diabetes patients: Join the QForma email list
Stay up to date with the latest news and information.